GlassScriptPhysician profile
Halie Leiker
NPI 1336771716
$3,378.66
in general payments reported to CMS, 2019-2025
28 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $719 · 2023: $308 · 2024: $621 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785 · Travel and Lodging: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.80 |
| Travel and Lodging | $726.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $967.61 | 2025 | Inspire |
| Boston Scientific Corporation | $588.61 | 2022 | |
| Genzyme Corporation | $176.14 | 2024-2025 | |
| Medtronic, INC. | $162.65 | 2021-2023 | Micra |
| E.R. Squibb & Sons, L.L.C. | $125.24 | 2022-2023 | Camzyos, Eliquis |
| United Therapeutics Corporation | $117.04 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $106.33 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $100.27 | 2022-2025 | Airsupra, Fasenra, Farxiga |
| Grifols USA, LLC | $97.53 | 2024-2025 | Prolastin-C Liquid |
| Daiichi Sankyo INC. | $94.79 | 2022-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $85.95 | 2022-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.84 | 2023-2024 | Lifevest |
| Pulmonx Corporation | $79.19 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Genentech USA, INC. | $73.22 | 2025 | Xolair |
| Philips North America LLC | $62.69 | 2024-2025 | Encore, Vest Therapy Und, (Ck4) Mcot |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $58.66 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $52.19 | 2024 | |
| Merck Sharp & Dohme LLC | $49.00 | 2023 | Verquvo |
| Verona Pharma, INC. | $46.76 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.96 | 2023-2024 | Ofev, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $33.02 | 2024-2025 | Glassia |
| Glaxosmithkline, LLC. | $32.51 | 2025 | Nucala |
| Cvrx, INC. | $29.27 | 2022-2024 | Barostim Neo System |
| Zoll Respicardia, INC. | $28.40 | 2025 | Remede System |
| Amgen INC. | $27.89 | 2024 | Tavneos |
| Surmodics, INC. | $24.82 | 2023 | Pounce Venous Thrombectomy System, Pounce Thrombectomy System, Sublime Radial Access 018 Rx Pta Dilatation Catheter |
| Actelion Pharmaceuticals US, INC. | $23.18 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $14.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halie Leiker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.